201 related articles for article (PubMed ID: 33828220)
21. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
22. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
[TBL] [Abstract][Full Text] [Related]
23. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon.
Fokam J; Salpini R; Santoro MM; Cento V; Perno CF; Colizzi V; Ndumbe PM; Fokunang Ntungen C; Ndiang Tetang SM; Nanfack AJ; Takou Komego DA; Cappelli G
Pediatr Infect Dis J; 2011 Dec; 30(12):1062-8. PubMed ID: 21817951
[TBL] [Abstract][Full Text] [Related]
24. Innate Immune Responses and Gut Microbiomes Distinguish HIV-Exposed from HIV-Unexposed Children in a Population-Specific Manner.
Amenyogbe N; Dimitriu P; Cho P; Ruck C; Fortuno ES; Cai B; Alimenti A; Côté HCF; Maan EJ; Slogrove AL; Esser M; Marchant A; Goetghebuer T; Shannon CP; Tebbutt SJ; Kollmann TR; Mohn WW; Smolen KK
J Immunol; 2020 Nov; 205(10):2618-2628. PubMed ID: 33067377
[TBL] [Abstract][Full Text] [Related]
25. Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients.
Imahashi M; Ode H; Kobayashi A; Nemoto M; Matsuda M; Hashiba C; Hamano A; Nakata Y; Mori M; Seko K; Nakahata M; Kogure A; Tanaka Y; Sugiura W; Yokomaku Y; Iwatani Y
Sci Rep; 2021 Jan; 11(1):960. PubMed ID: 33441754
[TBL] [Abstract][Full Text] [Related]
26. Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection.
Mak G; Zaunders JJ; Bailey M; Seddiki N; Rogers G; Leong L; Phan TG; Kelleher AD; Koelsch KK; Boyd MA; Danta M
Front Immunol; 2021; 12():688886. PubMed ID: 34135912
[TBL] [Abstract][Full Text] [Related]
27. Pediatric response to second-line antiretroviral therapy in South Africa.
Zanoni BC; Sunpath H; Feeney ME
PLoS One; 2012; 7(11):e49591. PubMed ID: 23185373
[TBL] [Abstract][Full Text] [Related]
28. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
[TBL] [Abstract][Full Text] [Related]
29. Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study.
Mossoro-Kpinde CD; Gody JC; Mboumba Bouassa RS; Moussa S; Jenabian MA; Péré H; Charpentier C; Matta M; Longo JD; Grésenguet G; Djoba Siawaya JF; Bélec L
Medicine (Baltimore); 2020 May; 99(21):e19978. PubMed ID: 32481261
[TBL] [Abstract][Full Text] [Related]
30. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
[TBL] [Abstract][Full Text] [Related]
31. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
32. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
[TBL] [Abstract][Full Text] [Related]
33. Alterations in children's sub-dominant gut microbiota by HIV infection and anti-retroviral therapy.
Nguyen QT; Ishizaki A; Bi X; Matsuda K; Nguyen LV; Pham HV; Phan CTT; Phung TTB; Ngo TTT; Nguyen AV; Khu DTK; Ichimura H
PLoS One; 2021; 16(10):e0258226. PubMed ID: 34634074
[TBL] [Abstract][Full Text] [Related]
34. Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals.
Xie Y; Sun J; Wei L; Jiang H; Hu C; Yang J; Huang Y; Ruan B; Zhu B
BMC Microbiol; 2021 Jan; 21(1):11. PubMed ID: 33407128
[TBL] [Abstract][Full Text] [Related]
35. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
36. Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy.
Lewy T; Hong BY; Weiser B; Burger H; Tremain A; Weinstock G; Anastos K; George MD
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):276-286. PubMed ID: 29808701
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
38. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy.
Lozupone CA; Rhodes ME; Neff CP; Fontenot AP; Campbell TB; Palmer BE
Gut Microbes; 2014 Jul; 5(4):562-70. PubMed ID: 25078714
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients.
Villanueva-Millán MJ; Pérez-Matute P; Recio-Fernández E; Lezana Rosales JM; Oteo JA
J Int AIDS Soc; 2017 Mar; 20(1):21526. PubMed ID: 28362071
[TBL] [Abstract][Full Text] [Related]
40. It is time to consider third-line options in antiretroviral-experienced paediatric patients?
Zyl GU; Rabie H; Nuttall JJ; Cotton MF
J Int AIDS Soc; 2011 Nov; 14():55. PubMed ID: 22085598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
